

Synthesis and antibiofilm and antibacterial activity evaluation of Tetrahydroindolone-Dihydropyrimidinone hybrids

Vinicius Vendrusculo,^{1,2*} Maria Paula L. S. de Oliveira,³ Belisa Á. Rodrigues,³ Karine R. Zimmer³ and Dennis Russowsky¹

1. Laboratory of Organic Synthesis, Federal University of Rio Grande do Sul, UFRGS, 91501-970

2. Teaching Department, Sul-rio-grandense Federal Institute, IFSul, 95800-000


3. Biofilms and Alternative Models Laboratory, Federal University of Health Sciences of Porto Alegre, UFCSPA, 90050-170

*e-mail: viniciusvendrusculo@ifsul.edu.br

Keywords: Hybridization, Dihydropyrimidinones, Antibiofilm

ABSTRACT

Tetrahydroindolones are important scaffolds in Medicinal Chemistry such as SNX2112, a heat shock protein (Hsp90) inhibitor and anti-cancer HER kinase dependent.¹ Likewise, Dihydropyrimidinones are bioactive compounds including antibacterial and anti-cancer activities.² The hybridization of bioactive compounds can lead to discovery of more efficient drugs with fewer side effects.³ Thus, Click CuAAC reaction of THI **3a-e** and azido-DHPM **4** afforded the hybrids *THI-DHPM* **5a-e**.



Scheme 1: General scheme for the synthesis of THI-DHPM hybrid compounds **5a-e**.

Biofilms are complex communities of microorganisms that adhere to surfaces and are embedded in a self-produced extracellular matrix that hinders the action of antibiotics. The antibiofilm activity of compounds **5a-e** at 100 µg/mL were evaluated against *Staphylococcus aureus* by crystal violet method.⁴

Table 1. Antibiofilm Activity of Hybrids THI-DHPM **5a-e** against *S. aureus*.

Entry	Compound	% of Biofilm Inhibition
1	5a	73
2	5b	78
3	5c	89
4	5d	31
5	5e	28
6	Vancomycin	72

The initial results have demonstrated the ability of **THI-DHPM** hybrids to inhibit the biofilm formation and bacterial growth. The bioactivity against *Pseudomonas aeruginosa* and the dose-response curves are under investigation as well as the toxicity in the *in vivo* model of *Caenorhabditis elegans*.

ACKNOWLEDGEMENTS

The authors would like to thank CAPES, FAPERGS, CNPQ and IFSUL for the financial support.

REFERENCES

- (1) Chandarlapaty, S. *et al.*, *Clin. Cancer Res.* **2008**, *14*, 240.
- (2) Matos, L.H.S. *et al.*, *Eur. J. Med. Chem.* **2018**, *143*, 1779.
- (3) Decker, M. *Design of Hybrid Molecules for Drug Development*; Elsevier: Amsterdam, 2017.
- (4) Ramos *et al.*, *Ind Crops Prod.* **2021**, *170*, 113713.